Novo Nordisk on Friday revealed disappointing results in a late-stage trial for its experimental next-generation obesity drug ...

Trials of semaglutide in patients with Alzheimer’s and CagriSema in obese patients diabetes could give investors reason to be ...

Novo Nordisk has an opportunity to expand indications on its weight loss drugs. Check out on what could be next for NVO stock ...

Novo Nordisk ADR (NYSE: NVO) currently trades at $89 per share, nearly 40% below its peak level of over $145 seen in June of ...

The drug helped patients reduce their weight by only 22.7 per cent, falling short of the anticipated result. Novo’s shares ...

Novo Nordisk shareholders were seeking on Friday to find out why such a high number of patients in the late-stage trial of ...

Novo Nordisk's CagriSema Phase 3 data showed 22.7% weight loss, missing the company's own 25% target, causing a 20% drop in ...

Novo shares lost nearly a fifth of their value after an experimental combination treatment called cagrisema fell short of the ...

Novo Nordisk said on Friday its experimental next-generation obesity drug CagriSema helped overweight patients cut their ...

As of 11:05 a.m. ET, Novo Nordisk stock is down a disheartening 20.8%, while both Lilly and Viking stocks are up 4.4% apiece.

Investing.com -- Novo Nordisk (CSE: NOVOb ) shares jumped over 9% on Monday, despite the company’s disappointing results for ...

Shares of Danish pharmaceutical giant Novo Nordisk plummeted more than 24% at one point on Friday after reporting trial ...